Table 1.
HIV-1-related characteristics of pregnant women at enrollment, overall and according to maternal body mass index adjusted for length of gestation (adjBMI) at enrollment
| Maternal adjBMI (kg/m2) at Enrollment | ||||||
|---|---|---|---|---|---|---|
| Underweight | Normal | Over-Weight | Obese | |||
| Overall | (≥10.0 - <19.8) | (≥19.8 - <26.1) | (≥26.1 - <29.0) | (≥29.0 - <50.0) | ||
| Enrollment characteristic | N=697 | n=109 | n=418 | n=88 | n=82 | P value 1 |
| Duration of HIV-1 diagnosis prior to enrollment (months): | ||||||
| Mean (SD) | 18.9 (26.9) | 16.2 (23.3) | 20.2 (27.8) | 15.1 (22.4) | 19.6 (31.4) | |
| Median | 5.0 | 4.0 | 5.0 | 4.0 | 5.0 | 0.56 |
| CDC disease classification: n (%) | ||||||
| Category A | 599 | 91 (16.2) | 351 (58.6) | 83 (13.9) | 74 (12.4) | |
| Category B | 42 | 7 (16.7) | 29 (69.0) | 2 (4.8) | 4 (9.5) | |
| Category C | 56 | 11 (19.6) | 38 (67.9) | 3 (5.4) | 4 (7.1) | 0.21 |
| Plasma HIV-1 RNA concentration (copies/mL): | ||||||
| Mean (SD) | 19037 (78608) | 15179 (53015) | 19675 (84660) | 23851 (83524) | 15741 (69695) | |
| Median | 452.0 | 653.0 | 470.5 | 227.0 | 332.5 | 0.32 |
| Absolute lymphocyte count (cells/mL): | ||||||
| Mean (SD) | 1494 (502) | 1383 (474) | 1475 (469) | 1580 (574) | 1652 (574) | |
| Median | 1440 | 1321 | 1433 | 1575 | 1584 | 0.0011 |
| CD4+ absolute count (cells/mm3): | ||||||
| Mean (SD) | 428 (221) | 421 (208) | 409 (212) | 503 (271) | 465 (209) | |
| Median | 397 | 384 | 378 | 456 | 424 | 0.011 |
| Antiretrovial regimen received at enrollment 2: n (%) | ||||||
| None | 161 | 28 (17.4) | 97 (60.3) | 18 (11.2) | 18 (11.2) | |
| 1 NRTI | 57 | 11 (19.3) | 24 (42.1) | 12 (21.1) | 10 (17.5) | |
| 2 NRTIs | 30 | 4 (13.3) | 21 (70.0) | 2 (6.7) | 3 (10.0) | |
| 2 NRTIs + 1 NNRTI | 190 | 23 (12.1) | 112 (59.0) | 27 (14.2) | 28 (14.7) | |
| 2 NRTIs + 1 PI | 247 | 43 (17.4) | 156 (63.2) | 26 (10.5) | 22 (8.9) | |
| Other | 12 | 0 | 8 (66.7) | 3 (25.0) | 1 (8.3) | 0.13 |
1
The p-values for associations between maternal BMI at enrollment and categorical characteristics are based on the Fisher-Freeman-Halton exact test, while those for associations with continuous scaled characteristics are based on the non-parametric Kruskal-Wallis test of equality of means.
2
Maternal ARV regimen at the time of enrollment was categorized as: one or two nucleoside reverse transcriptase inhibitors (NRTIs), two NRTIs with one non-nucleoside reverse transcriptase inhibitor (NNRTI) (HAART/NNRTI), two NRTIs with one PI (HAART/PI), or ”Other”.